Skip to main content
Premium Trial:

Request an Annual Quote

Lineagen Raises $5M, Closes Series A Round

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Genetic diagnostics development firm Lineagen today announced it has raised $5 million bringing the total for its Series A financing round to $10.8 million.

The company, which raised $5.8 million in the first close of the round in 2007, will use the funds to further develop Lineagen's lead autism program and support its planned commercial service launch in September, it said in a statement.

Participants in the most recent tranche include new investor PrairieGold Venture Partners and existing partners Sanderling Ventures, vSpring Capital, and Mesa Verde Venture Partners.

Mike Jerstad, a partner in PrairieGold, will join the board of Lineagen, which is based in Salt Lake City.

The company is developing genomic tests and services for "complex" diseases, such as autism, multiple sclerosis, and COPD.

The Scan

Steps for Quick Review

The US Food and Drug Administration is preparing for the quick review of drugs and vaccines for the Omicron variant, according to the Wall Street Journal.

Moving Away From Using Term 'Race'

A new analysis finds that geneticists are using the term "race" in their papers less than in years past, as Science reports.

Point of the Program

The Guardian writes that some scientists have called the design of a UK newborn sequencing program into question.

Science Papers Present Multi-Omic Analysis of Lung Cells, Regulation of Cardiomyocyte Proliferation

In Science this week: a multi-omic analysis of lung cells focuses on RIT1-regulated pathways, and more.